Hit enter to search or ESC to close
No menu assigned
News
COMPASS Pathways
COMPASS Pathways Announces Up to $285 Million Private Placement Financing
AUG 16, 2023
AN2 Therapeutics
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
AUG 15, 2023
Taysha Gene Therapies
Taysha Gene Therapies Announces $150 Million Private Placement Financing
AUG 14, 2023
ADARx Pharmaceuticals
ADARx Pharmaceuticals Announces Oversubscribed $200 Million Series C Financing
AUG 9, 2023
Gracell Biotechnologies
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing
AUG 7, 2023
Versanis
Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
JULY 13, 2023
Savara
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock
JULY 13, 2023
Upstream Bio
Upstream Bio Announces $200M Series B Financing
JUNE 8, 2023
Alkeus
Alkeus Announces $150 Million Series B Financing
JUNE 5, 2023
Carmot
Carmot Therapeutics Raises $150 Million in Series E
MAY 25, 2023
VectivBio
Ironwood Enters into Definitive Agreement to Acquire VectivBio
MAY 22, 2023
Icosavax
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
MAY 22, 2023
Iveric Bio
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
APRIL 30, 2023
Madrigal
Madrigal Announces Positive Topline Results from the Pivotal Phase 3
DECEMBER 19, 2022
Geron
Geron Announces Positive Top-Line Results from IMerge Phase 3
JANUARY 4, 2023
Abivax
Abivax announces successful oversubscribed EUR 130M cross-over financing
FEBRUARY 22, 2023
Structure Therapeutics
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
FEBRUARY 2, 2023
VectivBio
VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
OCTOBER 13, 2022
Immunovant
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
OCTOBER 4, 2022
Allakos
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
SEPTEMBER 19, 2022
Abivax
Abivax announces successful oversubscribed EUR 49.2M cross-over financing
SEPTEMBER 2, 2022
Upstream Bio
Upstream Bio Launches with $200M Series A
JUNE 2, 2022
Plexium
Plexium Announces $102M Financing
FEBRUARY 23, 2022
Eikon Therapeutics
Eikon Therapeutics Announces $517.8 Million Series B Raise
JANUARY 6, 2022
Arbor Biotechnologies
Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing
NOVEMBER 9, 2021
Entrada Therapeutics
Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering
OCTOBER 28, 2021
ShouTi
ShouTi Secures $100 Million Series B Financing
OCTOBER 20, 2021
Obsidian
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
SEPTEMBER 9, 2021
Artios
Artios Announces $153 Million Series C Financing
JULY 27, 2021
RayzeBio
RayzeBio Secures $108 Million Series C Financing
JUNE 15, 2021
Synthekine
Synthekine Announces $107.5 Million Oversubscribed Series B Financing
JUNE 10, 2021
Affinia Therapeutics
Affinia Therapeutics Closes $110 Million Series B Financing
MAY 3, 2021
TCG X
TCG X Raises Inaugural $824 Million Fund to Advance Disruptive Medicines
APRIL 20, 2021
Entrada Therapeutics
Entrada Therapeutics Announces Closing of $116 Million Series B Financing
MARCH 31, 2021
Aktis Oncology
Aktis Oncology Announces $72 Million Series A Financing to Advance Breakthrough Radiopharmaceuticals
MARCH 18, 2021
Home
About Us
Our Team
Portfolio
News
Contact